Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUPREP oral sulfate solution + Gastrografin is a combination regimen primarily utilized for bowel cleansing and fecal tagging prior to diagnostic imaging procedures, most notably CT colonography (virtual colonoscopy). SUPREP is an osmotic laxative containing sodium sulfate, potassium sulfate, and magnesium sulfate; it works by creating a high osmotic pressure within the intestinal lumen, drawing water into the bowel to induce diarrhea and clear fecal matter. Gastrografin is a water-soluble, iodinated radiopaque contrast medium composed of diatrizoate meglumine and diatrizoate sodium. When administered as part of a bowel preparation protocol, Gastrografin serves as a 'tagging' agent, opacifying any residual fluid or stool. This allows radiologists to distinguish between retained colonic contents and potentially significant lesions like polyps or colorectal cancer, thereby improving the sensitivity and specificity of the diagnostic imaging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium sulfate + potassium sulfate + magnesium sulfate + diatrizoate meglumine + diatrizoate sodium.